Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Oral Crohn's Disease: The proof is in the "cinnamon-free" pudding.

Crooks B, Probert CS, Limdi JK.

Clin Gastroenterol Hepatol. 2019 Sep 11. pii: S1542-3565(19)30988-7. doi: 10.1016/j.cgh.2019.09.005. [Epub ahead of print] No abstract available.

PMID:
31520729
2.

DNA extraction and amplicon production strategies deeply inf luence the outcome of gut mycobiome studies.

Frau A, Kenny JG, Lenzi L, Campbell BJ, Ijaz UZ, Duckworth CA, Burkitt MD, Hall N, Anson J, Darby AC, Probert CSJ.

Sci Rep. 2019 Jun 27;9(1):9328. doi: 10.1038/s41598-019-44974-x.

3.

Potential role of fecal volatile organic compounds as biomarkers of chemically induced intestinal inflammation in mice.

Reade S, Williams JM, Aggio R, Duckworth CA, Mahalhal A, Hough R, Pritchard DM, Probert CS.

FASEB J. 2019 Mar;33(3):3129-3136. doi: 10.1096/fj.201800076RR. Epub 2018 Oct 25.

PMID:
30359099
4.

Oral iron exacerbates colitis and influences the intestinal microbiome.

Mahalhal A, Williams JM, Johnson S, Ellaby N, Duckworth CA, Burkitt MD, Liu X, Hold GL, Campbell BJ, Pritchard DM, Probert CS.

PLoS One. 2018 Oct 11;13(10):e0202460. doi: 10.1371/journal.pone.0202460. eCollection 2018.

5.

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).

Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, Tate H, Wheeler C, Irving PM.

BMJ Open Gastroenterol. 2018 Jul 7;5(1):e000212. doi: 10.1136/bmjgast-2018-000212. eCollection 2018.

6.

Gastrointestinal malignancies at five regional referral hospitals in Uganda.

Obayo S, Lukwago L, Orem J, Faulx AL, Probert CS.

Afr Health Sci. 2017 Dec;17(4):1051-1058. doi: 10.4314/ahs.v17i4.13.

7.

Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial.

Bomhof MR, Parnell JA, Ramay HR, Crotty P, Rioux KP, Probert CS, Jayakumar S, Raman M, Reimer RA.

Eur J Nutr. 2019 Jun;58(4):1735-1745. doi: 10.1007/s00394-018-1721-2. Epub 2018 May 19.

PMID:
29779170
8.

Intestinal Enteroendocrine Lineage Cells Possess Homeostatic and Injury-Inducible Stem Cell Activity.

Yan KS, Gevaert O, Zheng GXY, Anchang B, Probert CS, Larkin KA, Davies PS, Cheng ZF, Kaddis JS, Han A, Roelf K, Calderon RI, Cynn E, Hu X, Mandleywala K, Wilhelmy J, Grimes SM, Corney DC, Boutet SC, Terry JM, Belgrader P, Ziraldo SB, Mikkelsen TS, Wang F, von Furstenberg RJ, Smith NR, Chandrakesan P, May R, Chrissy MAS, Jain R, Cartwright CA, Niland JC, Hong YK, Carrington J, Breault DT, Epstein J, Houchen CW, Lynch JP, Martin MG, Plevritis SK, Curtis C, Ji HP, Li L, Henning SJ, Wong MH, Kuo CJ.

Cell Stem Cell. 2017 Jul 6;21(1):78-90.e6. doi: 10.1016/j.stem.2017.06.014.

9.

Mechanisms Affecting the Gut of Preterm Infants in Enteral Feeding Trials.

Embleton ND, Berrington JE, Dorling J, Ewer AK, Juszczak E, Kirby JA, Lamb CA, Lanyon CV, McGuire W, Probert CS, Rushton SP, Shirley MD, Stewart CJ, Cummings SP.

Front Nutr. 2017 May 8;4:14. doi: 10.3389/fnut.2017.00014. eCollection 2017.

10.

Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury.

Carr DF, Ayehunie S, Davies A, Duckworth CA, French S, Hall N, Hussain S, Mellor HR, Norris A, Park BK, Penrose A, Pritchard DM, Probert CS, Ramaiah S, Sadler C, Schmitt M, Shaw A, Sidaway JE, Vries RG, Wagoner M, Pirmohamed M.

Pharmacol Ther. 2017 Apr;172:181-194. doi: 10.1016/j.pharmthera.2017.01.002. Epub 2017 Jan 27. Review.

PMID:
28132905
11.

Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis.

Aggio RB, White P, Jayasena H, de Lacy Costello B, Ratcliffe NM, Probert CS.

Aliment Pharmacol Ther. 2017 Jan;45(1):82-90. doi: 10.1111/apt.13822. Epub 2016 Nov 10.

12.

Microsporidia Intracellular Development Relies on Myc Interaction Network Transcription Factors in the Host.

Botts MR, Cohen LB, Probert CS, Wu F, Troemel ER.

G3 (Bethesda). 2016 Sep 8;6(9):2707-16. doi: 10.1534/g3.116.029983.

13.

Importance of the alternative NF-κB activation pathway in inflammation-associated gastrointestinal carcinogenesis.

Merga YJ, O'Hara A, Burkitt MD, Duckworth CA, Probert CS, Campbell BJ, Pritchard DM.

Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1081-90. doi: 10.1152/ajpgi.00026.2016. Epub 2016 Apr 21. Review.

14.

Unique microbial-derived volatile organic compounds in portal venous circulation in murine non-alcoholic fatty liver disease.

Reid DT, McDonald B, Khalid T, Vo T, Schenck LP, Surette MG, Beck PL, Reimer RA, Probert CS, Rioux KP, Eksteen B.

Biochim Biophys Acta. 2016 Jul;1862(7):1337-44. doi: 10.1016/j.bbadis.2016.04.005. Epub 2016 Apr 13.

15.

Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort.

Bond AD, Burkitt MD, Sawbridge D, Corfe BM, Probert CS.

J Gastrointestin Liver Dis. 2016 Mar;25(1):71-7. doi: 10.15403/jgld.2014.1121.251.m2p.

16.

Upper gastrointestinal diseases in patients for endoscopy in South-Western Uganda.

Obayo S, Muzoora C, Ocama P, Cooney MM, Wilson T, Probert CS.

Afr Health Sci. 2015 Sep;15(3):959-66. doi: 10.4314/ahs.v15i3.33.

17.

Freeze-drying: an alternative method for the analysis of volatile organic compounds in the headspace of urine samples using solid phase micro-extraction coupled to gas chromatography - mass spectrometry.

Aggio RB, Mayor A, Coyle S, Reade S, Khalid T, Ratcliffe NM, Probert CS.

Chem Cent J. 2016 Mar 1;10:9. doi: 10.1186/s13065-016-0155-2. eCollection 2016.

18.

The use of a gas chromatography-sensor system combined with advanced statistical methods, towards the diagnosis of urological malignancies.

Aggio RB, de Lacy Costello B, White P, Khalid T, Ratcliffe NM, Persad R, Probert CS.

J Breath Res. 2016 Feb 11;10(1):017106. doi: 10.1088/1752-7155/10/1/017106.

19.

Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease.

Ahmed I, Greenwood R, Costello B, Ratcliffe N, Probert CS.

Aliment Pharmacol Ther. 2016 Mar;43(5):596-611. doi: 10.1111/apt.13522. Epub 2016 Jan 25.

20.

Urinary Volatile Organic Compounds for the Detection of Prostate Cancer.

Khalid T, Aggio R, White P, De Lacy Costello B, Persad R, Al-Kateb H, Jones P, Probert CS, Ratcliffe N.

PLoS One. 2015 Nov 24;10(11):e0143283. doi: 10.1371/journal.pone.0143283. eCollection 2015.

21.

Review article: cytomegalovirus and inflammatory bowel disease.

Sager K, Alam S, Bond A, Chinnappan L, Probert CS.

Aliment Pharmacol Ther. 2015 Apr;41(8):725-33. doi: 10.1111/apt.13124. Epub 2015 Feb 16. Review.

22.

Identifying and quantifying metabolites by scoring peaks of GC-MS data.

Aggio RB, Mayor A, Reade S, Probert CS, Ruggiero K.

BMC Bioinformatics. 2014 Dec 10;15:374. doi: 10.1186/s12859-014-0374-2.

23.

Fecal volatile organic compounds: a novel, cheaper method of diagnosing inflammatory bowel disease?

Probert CS, Reade S, Ahmed I.

Expert Rev Clin Immunol. 2014 Sep;10(9):1129-31. doi: 10.1586/1744666X.2014.943664. Epub 2014 Jul 28.

PMID:
25066268
24.

Towards point of care testing for C. difficile infection by volatile profiling, using the combination of a short multi-capillary gas chromatography column with metal oxide sensor detection.

McGuire ND, Ewen RJ, de Lacy Costello B, Garner CE, Probert CS, Vaughan K, Ratcliffe NM.

Meas Sci Technol. 2014 May 12;25(6). pii: 065108.

25.

The use of a gas chromatograph coupled to a metal oxide sensor for rapid assessment of stool samples from irritable bowel syndrome and inflammatory bowel disease patients.

Shepherd SF, McGuire ND, de Lacy Costello BP, Ewen RJ, Jayasena DH, Vaughan K, Ahmed I, Probert CS, Ratcliffe NM.

J Breath Res. 2014 Jun;8(2):026001. doi: 10.1088/1752-7155/8/2/026001. Epub 2014 Mar 27.

26.

Early use of azathioprine in Crohn's disease.

Hawthorne AB, Probert CS, Sanderson JD.

Gastroenterology. 2014 Mar;146(3):865-6. doi: 10.1053/j.gastro.2013.10.072. Epub 2014 Jan 24. No abstract available.

PMID:
24468182
27.

A rare cause of weight loss.

Flanagan PK, Coupland SE, Arumainathan A, Probert CS.

Gut. 2014 Jun;63(6):1024, 1027. doi: 10.1136/gutjnl-2013-306299. Epub 2013 Nov 25. No abstract available.

PMID:
24277727
28.

The liver breath! Breath volatile organic compounds for the diagnosis of liver disease.

Khalid T, Richardson P, Probert CS.

Clin Gastroenterol Hepatol. 2014 Mar;12(3):524-6. doi: 10.1016/j.cgh.2013.10.032. Epub 2013 Nov 7. No abstract available.

PMID:
24211289
29.

Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.

Probert CS, Dignass AU, Lindgren S, Oudkerk Pool M, Marteau P.

J Crohns Colitis. 2014 Mar;8(3):200-7. doi: 10.1016/j.crohns.2013.08.007. Epub 2013 Sep 4.

30.

New insights on fibrosis in Crohn's disease.

Bailey JR, Whiting CV, Tarlton JF, Bland PW, Probert CS.

Expert Rev Gastroenterol Hepatol. 2013 Aug;7(6):497-9. doi: 10.1586/17474124.2013.814931. No abstract available.

PMID:
23984996
31.

A pilot study combining a GC-sensor device with a statistical model for the identification of bladder cancer from urine headspace.

Khalid T, White P, De Lacy Costello B, Persad R, Ewen R, Johnson E, Probert CS, Ratcliffe N.

PLoS One. 2013 Jul 8;8(7):e69602. doi: 10.1371/journal.pone.0069602. Print 2013.

32.

An investigation of fecal volatile organic metabolites in irritable bowel syndrome.

Ahmed I, Greenwood R, Costello Bde L, Ratcliffe NM, Probert CS.

PLoS One. 2013;8(3):e58204. doi: 10.1371/journal.pone.0058204. Epub 2013 Mar 13.

33.

Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.

Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, Bailey J, Myers RP, Rioux KP.

Clin Gastroenterol Hepatol. 2013 Jul;11(7):868-75.e1-3. doi: 10.1016/j.cgh.2013.02.015. Epub 2013 Feb 27.

PMID:
23454028
34.

Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.

Flourié B, Hagège H, Tucat G, Maetz D, Hébuterne X, Kuyvenhoven JP, Tan TG, Pierik MJ, Masclee AA, Dewit O, Probert CS, Aoucheta D; MOTUS study investigators.

Aliment Pharmacol Ther. 2013 Apr;37(8):767-75. doi: 10.1111/apt.12266. Epub 2013 Mar 4.

35.

Volatiles from oral anaerobes confounding breath biomarker discovery.

Khalid TY, Saad S, Greenman J, de Lacy Costello B, Probert CS, Ratcliffe NM.

J Breath Res. 2013 Mar;7(1):017114. doi: 10.1088/1752-7155/7/1/017114. Epub 2013 Feb 27.

PMID:
23446221
36.

IL-13 promotes collagen accumulation in Crohn's disease fibrosis by down-regulation of fibroblast MMP synthesis: a role for innate lymphoid cells?

Bailey JR, Bland PW, Tarlton JF, Peters I, Moorghen M, Sylvester PA, Probert CS, Whiting CV.

PLoS One. 2012;7(12):e52332. doi: 10.1371/journal.pone.0052332. Epub 2012 Dec 31.

37.

Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy.

Buda A, De Bona M, Dotti I, Piselli P, Zabeo E, Barbazza R, Bellumat A, Valiante F, Nardon E, Probert CS, Pignatelli M, Stanta G, Sturniolo GC, De Boni M.

Clin Transl Gastroenterol. 2012 Jan 5;3:e6. doi: 10.1038/ctg.2011.5.

38.

Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis.

Sands BE, Sandborn WJ, Creed TJ, Dayan CM, Dhanda AD, Van Assche GA, Greguš M, Sood A, Choudhuri G, Stempien MJ, Levitt D, Probert CS.

Gastroenterology. 2012 Aug;143(2):356-64.e1. doi: 10.1053/j.gastro.2012.04.043. Epub 2012 Apr 28.

PMID:
22549092
39.

Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?

Dhanda AD, Creed TJ, Greenwood R, Sands BE, Probert CS.

Inflamm Bowel Dis. 2012 Nov;18(11):2056-62. doi: 10.1002/ibd.22879. Epub 2012 Jan 23.

PMID:
22271464
40.

One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis.

Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, Hood K, Probert CS.

Inflamm Bowel Dis. 2012 Oct;18(10):1885-93. doi: 10.1002/ibd.21938. Epub 2011 Nov 13.

41.

Identification and characterisation of an iron-responsive candidate probiotic.

Bailey JR, Probert CS, Cogan TA.

PLoS One. 2011;6(10):e26507. doi: 10.1371/journal.pone.0026507. Epub 2011 Oct 19.

42.

Role of faecal gas analysis for the diagnosis of IBD.

Probert CS.

Biochem Soc Trans. 2011 Aug;39(4):1079-80. doi: 10.1042/BST0391079.

PMID:
21787351
43.

The molecular biology of inflammatory bowel diseases.

Corfield AP, Wallace HM, Probert CS.

Biochem Soc Trans. 2011 Aug;39(4):1057-60. doi: 10.1042/BST0391057.

PMID:
21787347
44.

Can 11β-hydroxysteroid dehydrogenase activity predict the sensitivity of bone to therapeutic glucocorticoids in inflammatory bowel disease?

Cooper MS, Kriel H, Sayers A, Fraser WD, Williams AM, Stewart PM, Probert CS, Tobias JH.

Calcif Tissue Int. 2011 Sep;89(3):246-51. doi: 10.1007/s00223-011-9512-2. Epub 2011 Jun 22.

PMID:
21695543
45.

A costly diagnostic failure.

Assadsangabi A, Probert CS, Pope I.

J Fam Pract. 2010 Nov;59(11):624-6. No abstract available.

PMID:
21090397
46.

Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine.

Munkholm P, Michetti P, Probert CS, Elkjaer M, Marteau P.

Eur J Gastroenterol Hepatol. 2010 Aug;22(8):912-6. Review.

PMID:
20665988
47.

Clinical experience of methotrexate in Crohn's disease: response, safety and monitoring of treatment.

Parker R, Dixit A, Fraser A, Creed TJ, Probert CS.

Postgrad Med J. 2010 Apr;86(1014):208-11. doi: 10.1136/pgmj.2009.085787. Erratum in: Postgrad Med J. 2011 Mar;87(1025):242. Dixit, Anyinda [corrected to Dixit, Anindya].

PMID:
20354043
48.

Mortality in ulcerative colitis-what should we tell our patients? Three year mortality following admission for the treatment of ulcerative colitis: a 6 year retrospective case review.

Falvey J, Greenwood R, Creed TJ, Smithson J, Sylvester P, Fraser A, Probert CS.

Frontline Gastroenterol. 2010 Apr;1(1):35-41. doi: 10.1136/fg.2009.000216. Epub 2010 Apr 1.

49.

IL-6 may modulate the skeletal response to glucocorticoids during exacerbations of inflammatory bowel disease.

Kriel M, Sayers A, Fraser WD, Williams AM, Koch A, Zacharowski K, Probert CS, Tobias JH.

Calcif Tissue Int. 2010 May;86(5):375-81. doi: 10.1007/s00223-010-9345-4. Epub 2010 Mar 14.

PMID:
20229252
50.

Volatile organic compounds as diagnostic biomarkers in gastrointestinal and liver diseases.

Probert CS, Ahmed I, Khalid T, Johnson E, Smith S, Ratcliffe N.

J Gastrointestin Liver Dis. 2009 Sep;18(3):337-43. Review.

Supplemental Content

Loading ...
Support Center